72 results about "Cell generation" patented technology

The present disclosure provides compositions and methods for using fixed biological samples in partition-based assays. In at least one embodiment, the disclosure provides a composition comprising a fixed biological sample and an un-fixing agent contained in a partition, such as a discrete droplet. In some embodiments, the disclosure provides un-fixing agent compounds capable of catalytically cleaving crosslinks in fixed biological samples, particularly crosslinked nucleic acids, such as RNA.

To provide a manufacturing system and method for creating multiple tissue constructs from cells.SOLUTION: A system can include a thaw subsystem (if the cells are provided in a frozen state), an expansion subsystem, a concentration subsystem, and a tissue maturation subsystem. Each of these subsystems is modular and can be reconfigured, and a process can be repeated depending on the specific tissue process being implemented. Multiple tissue types can be combined in multiple bioreactors. The activities of multiple bioreactors can be coordinated and controlled in an automated manner by a supervisor controller. The supervisor controller can receive user input at the start of the process, and can manage the process thereafter, alerting the user if user actions are required.SELECTED DRAWING: None

The invention relates to the technical field of cell data analysis, and discloses a single-cell transcriptome data and text description conjoint analysis method based on a multi-modal language model, which comprises the following steps: acquiring a single-cell RNA sequencing expression matrix and a corresponding cell text description, preprocessing the single-cell RNA sequencing expression matrix and the corresponding cell text description, and analyzing the single-cell transcriptome data and the corresponding cell text description; according to the method, a multi-modal data set is constructed, deep fusion of gene expression data and text knowledge is realized by constructing a double-model and cross-modal projection module, limitation of a single mode is avoided, a gene expression value and an index sequence are reserved during preprocessing, a rough coding mode is changed, and the cell type identification accuracy is improved; based on a pre-training strategy of comparative learning, matching learning and a cross-modal projection module, fine-grained cross-modal information interaction and sharing are realized, and cross-modal task effects of text generation cells or cell generation texts and the like are optimized.

The invention discloses a deep mutation scanning method based on protein-protein interaction in bacterial cells and a binding affinity prediction method. In the invention, split dCas9 proteins (SEQ ID NO.1 and SEQ ID NO.2) are respectively subjected to fusion expression with a receptor and a ligand with binding affinity to be detected, and are combined with a toxic sgRNA guide sequence (SEQ ID NO.3), and when PPI occurs, a toxic dCas9: sgRNA complex is formed to inhibit bacterial growth, so that a PPI affinity size signal is converted into a bacterial cell generation speed signal, and the signal can be quantified into a copy number value through next-generation sequencing. The invention further designs a deep learning binding affinity prediction model, high-affinity sequences can be screened from theoretical mutation space, the workload and cost of experimental verification are remarkably reduced, and a reliable basis is provided for subsequent protein function optimization and design.

The invention provides a method for generating platelet-like particles based on MEG-01 cells and evaluating functions of the platelet-like particles, and belongs to the technical field of cell biology. The invention provides a method for generating PLPs by inducing MEG-01 cells. According to the method, the MEG-01 cells are differentiated into PLPs with platelet characteristics by utilizing a PMA inducer. The PLPs disclosed by the invention has characteristic surface marker expression consistent with that of natural platelets, can respond to stimulation of an activator ADP, and shows biological functional characteristics of the platelets. The method for generating PLPs is simple and economical, experimental conditions are highly controllable, and an economical, efficient and repeatable in-vitro model is provided for functional research related to platelets.

Methods for generating human vascular leptomeningeal cells (VLMCs) from human oligodendrocyte progenitor cells (OPCs) are provided using chemically-defined culture media that allow for generation of differentiated cells in a 34-day culture protocol. Methods of generating human VLMCs from human pluripotent stem cells using chemically-defined culture media in a 40 day culture protocol are also provided. Culture media, isolated cell populations, and kits are also provided.

The invention relates to the field of cell engineering, in particular to application of Siglec7 in generation and / or release of exosomes in tumor cells. According to the invention, after a lentiviral vector of an overexpressed Siglec7 gene is constructed, tumor cells are transfected with the lentiviral vector, and finally the tumor cell strain stably expressing Siglec7 is obtained. Through extraction and detection, the cell strain obviously improves the yield of the exosome in unit cell and unit culture medium volume, and the yield of the exosome is obviously improved.

Among other things, techniques are described for spatially and temporally consistent ground modelling with information fusion. A vehicle location and orientation is obtained and an instantaneous ground height estimation is obtained for anchor cells of a grid map of the vehicle based on the obtained vehicle location and orientation. A pseudo ground height associated with non-anchor cells of the grid map is computed. A Bayesian filtering framework is used to generate a final ground height estimate for the anchor cells and the non-anchor cells based on the instantaneous ground height estimation for the anchor cells, the pseudo ground height associated with non-anchor cells, an estimated ground height from a previous timestamp, or any combinations thereof. The vehicle operates according to the final ground height estimate.

The invention discloses a method for large-scale production of engineered extracellular vesicles based on freeze-drying and hydration, which comprises the following steps: carrying out freeze dehydration treatment on cells, and then inducing the cells to generate target extracellular vesicles through hydration treatment. The method provided by the invention has good cross-cell type compatibility, is adaptive to suspension cells and adherent cells through a mild membrane reconstruction process, and has good biological safety. The invention further discloses the extracellular vesicles produced by the method and application of the extracellular vesicles.

The present disclosure relates to systems, non-transitory computer-readable media, and methods that analyze gene perturbation machine learning embeddings and clinical observation data sets utilizing machine learning, explainability models, and causal discovery models to generate causal predictions between one or more genes and clinical outcomes. Indeed, in one or more implementations, the disclosed systems identify gene perturbation embeddings generated from cells exposed to perturbations. For instance, the disclosed systems select a cluster of genes from a plurality of genes by applying a clustering model to the gene perturbation embeddings. In some instances, the disclosed systems select gene targets from the cluster of genes by using a machine learning classification model trained on a plurality of features of the clinical observation data set. Moreover, in some instances, the disclosed systems generate the causal prediction from the gene targets and the clinical observation data set utilizing a causal discovery model.

The present application relates to the technical field of cell function detection, and particularly relates to a method for evaluating cell function of HL-60 in monocyte activation test. The method comprises the following steps: (1) preparing HL-60 cell suspension; (2) stimulating with pyrogen; (3) quantifying total protein; (4) detecting by Western blotting; and (5) evaluating cell function. The method is based on Western blotting technology, and combines statistical analysis to realize objective and quantitative determination of the core functional index of the ability of synthesizing IL-6 protein under pyrogen stimulation, can accurately identify cells with pyrogen response function defects, provides clear experimental reference for selection of HL-60 cell generations, can pre-screen qualified cells, reduces pyrogen detection deviation caused by unqualified cell function and improper generations from the source, and effectively improves the reliability and repeatability of pyrogen detection results.

Single-cell multi-omics by co-encapsulating a single cell with two beads, the first an RNA barcoding bead having barcoded mRNA capture primer oligonucleotides attached on the bead surface; and the second a DNA barcoding bead having two types of oligonucleotides releasably attached to the surface: (1) barcoded adapter oligonucleotides that are complementary to oligonucleotides bound to the transposase that are eventually incorporated into gDNA fragments and (2) polyadenylated barcoded oligonucleotides containing the same barcode sequence as the adapters. In addition, integrated analysis of RNA and protein, including intracellular protein, from individual cells using similar co-encapsulation of a single cell, an RNA barcoding bead, and with / without a specific or non-specific protein binding bead in a microwell, to avoid protein fixation by first lysing the cell to liberate intracellular contents, and then capturing protein either on a solid surface or in solution with barcoded affinity reagents.

Provided here are methods directed to the T cell receptor cloning of heat shock protein 60 (HSP60), the generation of HSP60-specific regulatory T cells (Tregs), and adoptive cell transfer of HSP60-specific Tregs for the treatment of autoimmune and other disorders. Methods of treatment also include administering a therapeutically effective amount of an inhibitor of expression or activity of nucleus accumbens-associated protein- 1 (NAC1) along with the HSP60-specific Tregs.

The invention belongs to the technical field of biological medicine, and discloses a medicine for in-vivo engineering CAR-T and a preparation method thereof. The drug provided by the invention comprises a first RNA and a second RNA which are used for coding a chimeric antigen receptor in a specific molar ratio, the second RNA is used for coding at least two cytokines of CCL19, IL-17, IL-15, IL-2 or IL-24, by adopting the drug, the gene delivery efficiency and targeting of in-vivo engineered CAR-T can be improved, better T cell transformation and CAR + T cell generation effects are realized, the CAR-T cell depletion is reduced, and the drug has a good application prospect. According to the present invention, the CAR-T gene is constructed, such that the CAR-T gene can survive for a long time in the tumor microenvironment and continuously provide the treatment effect, has the excellent anti-tumor treatment effect, has the excellent application prospect in the in-vivo engineering CAR-T treatment, and has the important significance on the promotion of the efficient, safe and economical development of the CAR-T treatment.

The present application provides methods for generating human midbrain immature neurons and mature dopaminergic neurons from neural progenitor cells. In some embodiments, immature and mature midbrain neurons are obtained from neural progenitor cells, such as targeted midbrain neural stem cells (NSCs) and midbrain neural progenitor cells (midbrain NPCs), while they themselves are generated from human pluripotent stem cells. Methods for generating immature and mature neurons of the midbrain use a chemically defined medium that allows for the generation of mature dopaminergic neurons within a short of 23 days. Media, isolated cell populations, and kits are also provided.

The invention relates to the technical field of biological medicine, and particularly discloses an LNP-mRNA delivery system for generating CAR-T in vivo and application of the LNP-mRNA delivery system. The delivery system comprises lipid nanoparticles and CAR mRNA wrapped by the lipid nanoparticles, the lipid nanoparticles comprise SM102, cholesterol, DSPC and DMG-PEG2000, and the coding target protein of the CAR mRNA is CLDN18.2. The delivery system is applied to preparation of drugs for treating gastric cancer tumors. The obtained mRNA sequence can translate and express CAR protein targeting CLDN18.2, T cells can be encoded in situ in vivo through an LNP delivery system to generate CAR-T, the T cells are transformed into CAR-T cells in vivo, and a novel, convenient and universal implementation scheme is provided for CAR-T therapy.

The invention relates to the technical field of dendritic cell in-vitro induction methods, and provides a dendritic cell body and an in-vitro induction method and application thereof. Thymic stromal lymphopoietin; the invention relates to a recombinant human FLT3L-Fc fusion protein. And maturing stimulation combination. On the premise of avoiding complex use of equipment, the bottlenecks of DC yield, subgroup purity and functionality are broken through.

The current disclosure provides methods and compositions that provide for the insertion of transgenes in stem or progenitor cells without the deleterious effects to T cell differentiation by in vitro T cell differentiation methods. To accomplish this, the inventors have discovered that expression of the transgenes under the control of promoter regions, such as CD8a or CD8b, allows for the coordinated expression pattern that provides for both: 1) high expression of the transgene in mature T cells and 2) a coordinated level of expression of the transgene throughout the in vitro differentiation method that allows for the production of a population of mature T cells.

Methods for producing CD31 + VE-cadherin + KDR + endothelial cells (EC) using chemically defined media are provided, allowing EC production from early mesoderm progenitor cells in a short three days and EC production from pluripotent stem cells in a short five days. Media, isolated cell populations, and kits are also provided.

The invention discloses a device for auxiliary treatment of osteoarthritis by using mesenchymal stem cells, relates to the technical field of medical auxiliary instruments, and aims to solve the problems that an operator difficultly and conveniently observe the cell condition in real time due to the structural design of a current shaking-up device, and the cell condition cannot be conveniently observed when a culture dish is taken for observation; the technical problems that a stem cell culture solution is prone to making contact with outside air, and consequently culture fails and even pollution is caused are solved, a microscope is included, a shaking assembly located below an observation part is fixedly installed between the opposite faces of the bottom of the microscope, the shaking assembly comprises a supporting plate, and a supporting piece is fixedly installed at the top of the supporting plate; according to the invention, a base of a microscope is replaced by the swing assembly, so that an operator can directly observe the condition of the cells through the microscope when shaking up the cells in the culture dish, and the cell generation condition can be observed in real time in the shaking up process; and the cell culture effect is improved.

This invention relates to Natural Killer (NK) cell populations, to methods of producing the same and therapeutic applications thereof. More specifically, the invention relates to the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production.

The present invention relates generally to the field of CAR-T cells. Specifically, the present invention relates to improved methods for obtaining CAR-T cells, and improved CAR-T cells and uses thereof. The method further relates to activating or expressing phosphodiesterase (PDE) in T cells during CAR-T cell generation.

A method of selecting candidate T cell receptors (TCRs) or T cells expressing candidate TCRs with defined characteristics, comprising: a) generating single cell data from a plurality of T cells from a

The invention discloses a human immortalized fallopian tube fibroblast strain as well as a construction method and application thereof, and belongs to the technical field of cell immortalization construction. The preparation method comprises the following steps: firstly, separating, culturing and purifying fibroblasts from human fallopian tube tissues by virtue of an enzyme digestion method, identifying markers of the fibroblasts, then introducing a simian virus 40 large T antigen gene into primary fibroblasts by virtue of a lentiviral vector, and screening by virtue of puromycin to obtain a cell strain capable of stably expressing SV40T. Finally, the human immortalized fallopian tube fibroblast which can be stably passaged is constructed. The cell strain has the characteristics of strong multiplication capacity and high hereditary stability, and the cells are not obviously aged along with the increase of the number of generations of the cells, which indicates that the human immortalized fallopian tube fibroblast line is successfully established. According to the invention, the problem that the in-vitro culture life of primary fibroblasts is limited is solved, and a reliable in-vitro cell model is provided for research in the fields of fallopian tube related diseases, ovarian cancer origin, tumor microenvironment and the like.

The invention discloses pharmaceutical application of a P2Y11 specific inhibitor and a composition containing the P2Y11 specific inhibitor, and belongs to the technical field of biological medicine. The invention discloses application of NF157 in preparation of drugs related to treatment of HD5-promoted pathogenic infection for the first time. In the aspect of pathogen infection treatment, NF157 can specifically inhibit combination of P2Y11 and HD5, so that the effect that HD5 regulates cytoskeleton rearrangement to promote filamentous pseudopod generation is eliminated, and the NF157 becomes a key link for cutting off pathogen infection. By preventing the cells from generating filamentous pseudopod, the NF157 effectively blocks the capturing path of bacteria, and has a remarkable intervention effect on part of pathogens which are lack of adhesion devices and flagellum and are invaded by relying on cell pseudopod capturing.

The invention belongs to the technical field of biology, and particularly relates to a compound composition for inducing cell migration by controlling the curvature of a membrane and application. The preparation method comprises the following steps: by taking hemagglutinin protein as a membrane protein aggregation unit, connecting sialic acid lactose and rhodamine B in an acylhydrazone bond manner to form a binding and driving unit (R-SL small molecule induction ligand), so as to form self-assembled molecular tweezers (ATS); the preparation process is simple, and the equipment and labor cost is reduced. The constructed self-assembled molecular tweezers realize the polymerization / depolymerization process of membrane protein through a simple chemical regulation method, so that the membrane curvature is efficiently regulated; cell migration is obviously induced, and wound healing is promoted. The cell level test verifies that when the self-assembly molecular tweezers are used for adjusting the curvature of cells, the self-assembly molecular tweezers can promote the cells to generate pseudopods and induce the neogenesis of blood capillaries, and the self-assembly molecular tweezers have universality, induce cell migration and promote the healing process of wounds. The self-assembled molecular tweezers hydrogel does not pull a wound during replacement, so that the compliance of a patient is improved.

A pipe sheet (1) has: a sheet body (10); a first pipe (21) that is provided inside the sheet body (10) and that is for performing a first step in a cell culturing method; a second pipe (22) that is provided inside the sheet body (10) and is for performing a second step in the cell culturing method; first joints (30) that are provided to one opening end of the first pipe (21) and one opening end of the second pipe (22) and are detachably linked to another member; and second joints (40) that are provided to the other opening end of the first pipe (21) and the other opening end of the second pipe (22), and are detachably linked to another member. A first joint (30) of the first pipe (21) and a first joint (30) of the second pipe (22) are positioned at a first end (10a) of the sheet body (10). A second joint (40) of the first pipe (21) and a second joint (40) of the second pipe (22) are positioned at a second end (10b) of the sheet body (10).

This invention discloses a bismuth-copper bimetallic coordination nanomaterial, its preparation method, and its applications, belonging to the technical field of biofunctional materials. The prepared bismuth-copper bimetallic coordination nanomaterial can efficiently generate reactive oxygen species (ROS) under ultrasonic stimulation, initiating the sonodynamic therapy (SDT) process; the Cu in this material... 2+ The weakly acidic environment of the tumor microenvironment can also trigger a Fenton-like reaction, generating cytotoxic hydroxyl radicals (•OH) and oxygen in situ, thus initiating the chemokinetic therapy (CDT) process. Through the synergistic effect of sonodynamic therapy (SDT) and chemokinetic therapy (CDT), they jointly inhibit cancer cell proliferation and promote T cell generation.

The invention discloses a mammalian cell strain, a method for preparing a hog cholera virus soluble E2 recombinant antigen by using the mammalian cell strain and application of the mammalian cell strain. The mammalian cell expression system with different cell generations can stably express a large amount of soluble CSFV-E2 recombinant protein, so that the production cost for producing the hog cholera E2 protein is effectively reduced, and further the mammalian cell expression system can be applied to production of the hog cholera E2 protein subunit vaccine.

To provide a process for generating compositions of engineered cells.SOLUTION: A process comprises: (a) incubating, under stimulating conditions, an input composition comprising T cells enriched for CD4+ primary human T cells, the stimulating conditions comprising the presence of (i) a stimulatory reagent capable of activating one or more intracellular signaling domains of one or more components of a TCR complex and / or one or more intracellular signaling domains of one or more costimulatory molecules and (ii) one or more cytokines, wherein at least one cytokine is or comprises recombinant human IL-2, thereby generating a stimulated composition; and (b) introducing a recombinant receptor into the stimulated composition, thereby generating an engineered composition comprising engineered T cells.SELECTED DRAWING: Figure 1